Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation.
Overview
Abstract
Introduction: Glioblastoma (GBM) is a highly aggressive malignant brain tumor with persistently poor clinical outcomes and few effective treatment options. Arylsulfatase D (ARSD), a lysosomal sulfatase implicated in several cancers, has not been fully characterized in GBM.
Methods: ARSD expression in GBM was evaluated using bioinformatic analyses and immunohistochemical validation. ARSD was overexpressed or knocked down in U87MG, U251MG, and A172 cells, and proliferation, three-dimensional spheroid growth, apoptosis, invasion, and Matrigel-based tube-like network formation were assessed. Merlin/
Results: ARSD was upregulated in GBM tissues, and higher ARSD expression was associated with unfavorable patient survival. ARSD overexpression enhanced proliferation, three-dimensional spheroid growth, invasion, and Matrigel-based tube-like network formation while reducing apoptosis, whereas ARSD knockdown suppressed these malignant phenotypes. ARSD expression was associated with altered Merlin/
Discussion: These findings indicate that ARSD facilitates GBM malignant behavior and is linked to Merlin/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE103224, at NCBI GEO; found in the text, “Bioinformatics analysis”
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 7 authors, 7 keywords, 39 references.
Cite
This paper
Li, X., Hou, Q., Tang, Y., Wang, N., Zhong, C., Xu, L., & Wang, J. (2026). Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation. Frontiers in oncology, 16, 1927290. https://
BibTeX
@article{li2026arylsulfa
author = {Li, Xuzhao and Hou, Qifan and Tang, Yanli and Wang, Nianhua and Zhong, Chen and Xu, Lixin and Wang, Jun},
title = {{Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation}},
journal = {Frontiers in oncology},
year = {2026},
month = aug,
volume = {16},
pages = {1927290},
publisher = {Frontiers Media SA},
issn = {2234-943X},
doi = {10.3389/
url = {https://
pmid = {42707099},
pmcid = {PMC13547030}
}
RIS
TY - JOUR
AU - Li, Xuzhao
AU - Hou, Qifan
AU - Tang, Yanli
AU - Wang, Nianhua
AU - Zhong, Chen
AU - Xu, Lixin
AU - Wang, Jun
TI - Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation
T2 - Frontiers in oncology
J2 - Front Oncol
PY - 2026
DA - 2026/
VL - 16
SP - 1927290
SN - 2234-943X
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation",
"container-title": "Frontiers in oncology",
"author": [
{
"family": "Li",
"given": "Xuzhao"
},
{
"family": "Hou",
"given": "Qifan"
},
{
"family": "Tang",
"given": "Yanli"
},
{
"family": "Wang",
"given": "Nianhua"
},
{
"family": "Zhong",
"given": "Chen"
},
{
"family": "Xu",
"given": "Lixin"
},
{
"family": "Wang",
"given": "Jun"
}
],
"container-title-short":
"volume": "16",
"page": "1927290",
"DOI": "10.3389/
"PMID": "42707099",
"PMCID": "PMC13547030",
"ISSN": "2234-943X",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
24
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1177/11769351261460625
- GFAP-Dependent Transcriptional Dynamics and Cellular Heterogeneity in Primary, Recurrent, and Grade III Gliomas.Journal: Cancer informaticsIn common: NCBI GEO GSE103224, other condition, cellular / molecular, 2 references
- [2] doi:10.1186/s12935-026-04213-6
- Distinct molecular pathways leading to dosage-dependent temozolomide resistance in GBM stem cells.Journal: Cancer cell internationalIn common: other condition, cellular / molecular, 4 references
- [3] doi:10.1038/s41467-025-58366-5 [code]
- Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression.Journal: Nature communicationsIn common: NCBI GEO GSE103224, other condition, cellular / molecular
- [4] doi:10.1186/s12916-024-03775-4
- Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.Journal: BMC medicineIn common: other condition, 4 references
- [5] doi:10.3389/fimmu.2025.1581850
- Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis.Journal: Frontiers in immunologyIn common: NCBI GEO GSE103224, other condition
- [6] doi:10.3389/fphar.2023.1113182
- URB2 as an important marker for glioma prognosis and immunotherapy.Journal: Frontiers in pharmacologyIn common: NCBI GEO GSE103224, other condition
- [7] doi:10.32604/or.2026.079221
- Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.Journal: Oncology researchIn common: other condition, cellular / molecular, 4 references
- [8] doi:10.3892/or.2025.9025
- S100B drives glioblastoma invasion and migration through TGF‑β2‑mediated epithelial‑mesenchymal transition.Journal: Oncology reportsIn common: other condition, 4 references
- [9] doi:10.1038/s41598-025-05054-5
- Repurposing of CNS accumulating drugs Gemfibrozil and Doxylamine for enhanced sensitization of glioblastoma cells through modulation of autophagy.Journal: Scientific reportsIn common: other condition, cellular / molecular, 3 references
- [10] doi:10.3389/fonc.2023.1166207
- An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?Journal: Frontiers in oncologyIn common: other condition, cellular / molecular, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
